Show simple item record

dc.contributor.authorLudwig, H
dc.contributor.authorBoccadoro, M
dc.contributor.authorMoreau, P
dc.contributor.authorSan-Miguel, J
dc.contributor.authorCavo, M
dc.contributor.authorPawlyn, C
dc.contributor.authorZweegman, S
dc.contributor.authorFacon, T
dc.contributor.authorDriessen, C
dc.contributor.authorHajek, R
dc.contributor.authorDimopoulos, MA
dc.contributor.authorGay, F
dc.contributor.authorAvet-Loiseau, H
dc.contributor.authorTerpos, E
dc.contributor.authorZojer, N
dc.contributor.authorMohty, M
dc.contributor.authorMateos, M-V
dc.contributor.authorEinsele, H
dc.contributor.authorDelforge, M
dc.contributor.authorCaers, J
dc.contributor.authorWeisel, K
dc.contributor.authorJackson, G
dc.contributor.authorGarderet, L
dc.contributor.authorEngelhardt, M
dc.contributor.authorvan de Donk, N
dc.contributor.authorLeleu, X
dc.contributor.authorGoldschmidt, H
dc.contributor.authorBeksac, M
dc.contributor.authorNijhof, I
dc.contributor.authorAbildgaard, N
dc.contributor.authorBringhen, S
dc.contributor.authorSonneveld, P
dc.date.accessioned2020-10-22T14:33:54Z
dc.date.issued2021-01
dc.identifier.citationLeukemia, 2021, 35 (1), pp. 31 - 44
dc.identifier.issn0887-6924
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4191
dc.identifier.eissn1476-5551
dc.identifier.doi10.1038/s41375-020-01016-0
dc.description.abstractVaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
dc.formatPrint-Electronic
dc.format.extent31 - 44
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectCommunicable Diseases
dc.subjectMultiple Myeloma
dc.subjectImmunosuppressive Agents
dc.subjectVaccines
dc.subjectVaccination
dc.subjectConsensus
dc.subjectCommunicable Disease Control
dc.subjectEurope
dc.subjectClinical Trials as Topic
dc.subjectPractice Guidelines as Topic
dc.titleRecommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
dc.typeJournal Article
dcterms.dateAccepted2020-08-05
rioxxterms.versionofrecord10.1038/s41375-020-01016-0
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLeukemia
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.publication-statusPublished
pubs.volume35
pubs.embargo.termsNot known
icr.researchteamMyeloma Biology and Therapeuticsen_US
dc.contributor.icrauthorPawlyn, Charlotteen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0